BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1291 related articles for article (PubMed ID: 14685170)

  • 1. Met, metastasis, motility and more.
    Birchmeier C; Birchmeier W; Gherardi E; Vande Woude GF
    Nat Rev Mol Cell Biol; 2003 Dec; 4(12):915-25. PubMed ID: 14685170
    [No Abstract]   [Full Text] [Related]  

  • 2. Targeting the hepatocyte growth factor/Met pathway in cancer.
    De Silva DM; Roy A; Kato T; Cecchi F; Lee YH; Matsumoto K; Bottaro DP
    Biochem Soc Trans; 2017 Aug; 45(4):855-870. PubMed ID: 28673936
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The multisubstrate docking site of the MET receptor is dispensable for MET-mediated RAS signaling and cell scattering.
    Tulasne D; Paumelle R; Weidner KM; Vandenbunder B; Fafeur V
    Mol Biol Cell; 1999 Mar; 10(3):551-65. PubMed ID: 10069803
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The MET receptor tyrosine kinase in invasion and metastasis.
    Benvenuti S; Comoglio PM
    J Cell Physiol; 2007 Nov; 213(2):316-25. PubMed ID: 17607709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural and functional basis of the serine protease-like hepatocyte growth factor beta-chain in Met binding and signaling.
    Kirchhofer D; Yao X; Peek M; Eigenbrot C; Lipari MT; Billeci KL; Maun HR; Moran P; Santell L; Wiesmann C; Lazarus RA
    J Biol Chem; 2004 Sep; 279(38):39915-24. PubMed ID: 15218027
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The multisubstrate adapter Gab1 regulates hepatocyte growth factor (scatter factor)-c-Met signaling for cell survival and DNA repair.
    Fan S; Ma YX; Gao M; Yuan RQ; Meng Q; Goldberg ID; Rosen EM
    Mol Cell Biol; 2001 Aug; 21(15):4968-84. PubMed ID: 11438654
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatocyte growth factor/MET in cancer progression and biomarker discovery.
    Matsumoto K; Umitsu M; De Silva DM; Roy A; Bottaro DP
    Cancer Sci; 2017 Mar; 108(3):296-307. PubMed ID: 28064454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. State of the structure address on MET receptor activation by HGF.
    Linossi EM; Estevam GO; Oshima M; Fraser JS; Collisson EA; Jura N
    Biochem Soc Trans; 2021 Apr; 49(2):645-661. PubMed ID: 33860789
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phosphatase of regenerating liver sensitizes MET to functional activation by hepatocyte growth factor.
    Kojima T; Funato Y; Miki H
    Biochem J; 2019 May; 476(10):1419-1431. PubMed ID: 31036720
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dissociation of heparan sulfate and receptor binding domains of hepatocyte growth factor reveals that heparan sulfate-c-met interaction facilitates signaling.
    Rubin JS; Day RM; Breckenridge D; Atabey N; Taylor WG; Stahl SJ; Wingfield PT; Kaufman JD; Schwall R; Bottaro DP
    J Biol Chem; 2001 Aug; 276(35):32977-83. PubMed ID: 11435444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potent blockade of hepatocyte growth factor-stimulated cell motility, matrix invasion and branching morphogenesis by antagonists of Grb2 Src homology 2 domain interactions.
    Atabey N; Gao Y; Yao ZJ; Breckenridge D; Soon L; Soriano JV; Burke TR; Bottaro DP
    J Biol Chem; 2001 Apr; 276(17):14308-14. PubMed ID: 11278639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural basis of MET receptor dimerization by the bacterial invasion protein InlB and the HGF/SF splice variant NK1.
    Niemann HH
    Biochim Biophys Acta; 2013 Oct; 1834(10):2195-204. PubMed ID: 23123275
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An allosteric switch for pro-HGF/Met signaling using zymogen activator peptides.
    Landgraf KE; Steffek M; Quan C; Tom J; Yu C; Santell L; Maun HR; Eigenbrot C; Lazarus RA
    Nat Chem Biol; 2014 Jul; 10(7):567-73. PubMed ID: 24859116
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potent and selective inhibitors of the Met [hepatocyte growth factor/scatter factor (HGF/SF) receptor] tyrosine kinase block HGF/SF-induced tumor cell growth and invasion.
    Wang X; Le P; Liang C; Chan J; Kiewlich D; Miller T; Harris D; Sun L; Rice A; Vasile S; Blake RA; Howlett AR; Patel N; McMahon G; Lipson KE
    Mol Cancer Ther; 2003 Nov; 2(11):1085-92. PubMed ID: 14617781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the c-MET signaling pathway for cancer therapy.
    Liu X; Yao W; Newton RC; Scherle PA
    Expert Opin Investig Drugs; 2008 Jul; 17(7):997-1011. PubMed ID: 18549337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Invasive growth: a genetic program.
    Gentile A; Comoglio PM
    Int J Dev Biol; 2004; 48(5-6):451-6. PubMed ID: 15349819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Coupling of Gab1 to c-Met, Grb2, and Shp2 mediates biological responses.
    Schaeper U; Gehring NH; Fuchs KP; Sachs M; Kempkes B; Birchmeier W
    J Cell Biol; 2000 Jun; 149(7):1419-32. PubMed ID: 10871282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression array analysis of the hepatocyte growth factor invasive program.
    Cecchi F; Lih CJ; Lee YH; Walsh W; Rabe DC; Williams PM; Bottaro DP
    Clin Exp Metastasis; 2015 Oct; 32(7):659-76. PubMed ID: 26231668
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The biological role of HGF-MET axis in tumor growth and development of metastasis.
    Lesko E; Majka M
    Front Biosci; 2008 Jan; 13():1271-80. PubMed ID: 17981628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Essential role of Gab1 for signaling by the c-Met receptor in vivo.
    Sachs M; Brohmann H; Zechner D; Müller T; Hülsken J; Walther I; Schaeper U; Birchmeier C; Birchmeier W
    J Cell Biol; 2000 Sep; 150(6):1375-84. PubMed ID: 10995442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 65.